| REVIEW ARTICLE |
|
| Year : 2021 | Volume
: 6
| Issue : 1 | Page : 23-29 |
|
|
Evidence of superiority of sacubitril/valsartan versus angiotensin-converting enzyme inhibitors or angiotensin ii receptor blockers in the heart failure with reduced ejection fraction patient's journey
Mauro Gori, Emilia D'Elia, Michele Senni
Department of Cardiovascular, Papa Giovanni XXIII Hospital, Bergamo, Italy
Correspondence Address:
Michele Senni
Department of Cardiovascular, Papa Giovanni XXIII Hospital, Bergamo
Italy
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/2470-7511.312591
|
|
|
Sacubitril/valsartan (S/V) is a new drug which has been recently recommended by the international guidelines for the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF). Compared to angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs), S/V is associated with a better cardiovascular outcome, and to a greater beneficial effect on myocardial reverse remodeling. Recent evidence has shown that S/V is not only recommended in chronic patients but it is also approved in the acute setting; moreover, its safety and tolerability have been demonstrated also in the pediatric population. This review summarizes data on the effectiveness and tolerability of S/V in HFrEF patients and offers practical insights to manage this drug in every setting, providing an overview from randomized clinical trials' data to real-world evidence.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
